

# TARC IN PATIENTS WITH LYMPHADENOPATH, FEVER OR NON-HODGKIN LYMPHOMA

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Pending
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON23023

### Source

Nationaal Trial Register

### Brief title

TARC-002

### Health condition

-lymphadenopathy

-fever

-

## Sponsors and support

**Primary sponsor:** University Medical Center Groningen

**Source(s) of monetary or material Support:** initiator

## Intervention

## Outcome measures

### Primary outcome

Mean TARC levels (pg/mL) in correlation with final diagnosis

## Secondary outcome

Not applicable

## Study description

### Background summary

This is a prospective study to determine TARC levels in patients with lymph node enlargement of unknown origin, fever and in patients who are already diagnosed with non-Hodgkin lymphoma subtypes. TARC levels will be matched with final diagnosis and compared with TARC levels of healthy controls and patients with Hodgkin lymphoma, which have already been collected in previous studies.

### Study objective

The hypotheses of the study is that TARC levels in patients with fever, other causes of lymphadenopathy and non-Hodgkin lymphoma will be significantly lower compared to patients with Hodgkin lymphoma.

### Study design

at entry

### Intervention

ICF, venapunction once 10ml

## Contacts

### Public

W.J. Plattel  
Hanzeplein 1

Groningen 9713 GZ  
The Netherlands  
050-3611761

### Scientific

W.J. Plattel  
Hanzeplein 1

Groningen 9713 GZ  
The Netherlands  
050-3611761

## Eligibility criteria

### Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Age ≥ 18 years; - Ability to give written informed consent; And one of the following: (1) Lymph node enlargement of unknown cause for which a diagnostic fine needle aspiration will be performed or (2) Presenting with fever at the emergency department or (3) Presenting with newly diagnosed or relapsed nodular lymphocyte predominant or non-Hodgkin lymphoma.

### Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study (applicable to all subgroups): - Ineligibility to give written informed consent; - Patients with active atopic disease or hepatic failure; - Patients already diagnosed with Hodgkin lymphoma

## Study design

### Design

Study type:	Interventional
Intervention model:	Factorial
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

### Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	01-04-2017

Enrollment: 300  
Type: Anticipated

## Ethics review

Positive opinion  
Date: 02-02-2017  
Application type: First submission

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

### In other registers

Register	ID
NTR-new	NL6808
NTR-old	NTR6994
Other	:

## Study results